Roche Aktie

282,15 EUR +3,65 EUR +1,31 %

15:12:59

FSE

263,70 CHF +4,50 CHF +1,74 %

15:16:29

SWX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.221,09 Mrd. EUR

KGV24,60Div. Rendite3,80%

WKN855167

ISINCH0012032048

SymbolRHHVF

Roche Aktien News

Sortieren:Datum Meistgelesen

18.06.24PR NewswireRoche receives FDA clearance on its digital pathology solution for diagnostic use

15.06.24GlobeNewswireRoche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

10.06.24GlobeNewswireRoche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization

10.06.24GlobeNewswireEuropean Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer

07.06.24GlobeNewswireFive-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk

29.05.24GlobeNewswireFDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

27.05.24GlobeNewswireChanges to the Roche Enlarged Corporate Executive Committee

27.05.24PR NewswireRoche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing

22.05.24GlobeNewswireRoche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk

21.05.24GlobeNewswireFDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

16.05.24GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity

15.05.24GlobeNewswireRoche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer

24.04.24GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

19.04.24GlobeNewswireFDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

17.04.24GlobeNewswireRoche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

15.04.24GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study

11.04.24GlobeNewswireRoche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis

10.04.24PR NewswireRoche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU

26.03.24GlobeNewswireRoche receives FDA approval for the first molecular test to screen for malaria in blood donors

12.03.24GlobeNewswireRoche Annual General Meeting 2024

12.03.24PR NewswireRoche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024

05.03.24GlobeNewswireRoche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when add

25.02.24GlobeNewswireNew England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies

16.02.24GlobeNewswireFDA approves Xolair as first and only medicine for children and adults with one or more food allergies

13.02.24PR NewswireRoche enters into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics

12.02.24PR NewswireRoche launches three new Factor Xa inhibitor coagulation tests to meet growing patient need

01.02.24GlobeNewswireNew long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)

01.02.24GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline

30.01.24PR NewswireRoche is awarded IDC Best in Future of Intelligence award for implementing data mesh strategy at scale with Immuta

16.01.24GlobeNewswireEuropean Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types

03.01.24PR NewswireRemix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing

29.12.23GlobeNewswireRoche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform

19.12.23GlobeNewswireFDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results

19.12.23PR NewswireRoche navify digital solutions get excellent ratings from healthcare professionals in KLAS Research reports

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.